Edward McKone

7PUBLICATIONS
9CO-AUTHORS
Carbon capture engineering (excl. sequestration)Infant and child healthAircraft performance and flight control systemsBehavioural epidemiologyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 11, 2025
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Isabelle Durieu, Barry Clements, Benedetta Fabrizzi

|Jun 02, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.

Claire Wainwright, Susanna A McColley, Paul McNally

|Apr 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study.

Cori L Daines, Deepika Polineni, Elizabeth Tullis

|Oct 27, 2023
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.

Bonnie Ramsey, Christoph U Correll, David R DeMaso

|Sep 13, 2023
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.

Paul McNally, Karen Lester, Gavin Stone

|Mar 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.

Jennifer L Goralski, Jordana E Hoppe, Marcus A Mall

Pageof 2

Frequent Collaborators

5 joint publications

Marcus A Mall

3 joint publications

Jennifer L Taylor-Cousar

2 joint publications

Paul McNally

1 joint publications

Alessandro N Franciosi